company background image
SPEC logo

SpectraCure OM:SPEC Stock Report

Last Price

SEK 2.40

Market Cap

SEK 232.6m

7D

3.9%

1Y

-56.5%

Updated

05 Aug, 2024

Data

Company Financials

SPEC Stock Overview

Engages in the development of cancer treatment system.

SPEC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

SpectraCure AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for SpectraCure
Historical stock prices
Current Share PriceSEK 2.40
52 Week HighSEK 5.70
52 Week LowSEK 2.00
Beta0.70
11 Month Change0.42%
3 Month Change-22.74%
1 Year Change-56.45%
33 Year Change-78.48%
5 Year Change-90.96%
Change since IPO29.46%

Recent News & Updates

SpectraCure (STO:SPEC) Is In A Good Position To Deliver On Growth Plans

Jul 31
SpectraCure (STO:SPEC) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That SpectraCure (STO:SPEC) Will Use Its Cash Wisely

Feb 23
We're Hopeful That SpectraCure (STO:SPEC) Will Use Its Cash Wisely

Recent updates

SpectraCure (STO:SPEC) Is In A Good Position To Deliver On Growth Plans

Jul 31
SpectraCure (STO:SPEC) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That SpectraCure (STO:SPEC) Will Use Its Cash Wisely

Feb 23
We're Hopeful That SpectraCure (STO:SPEC) Will Use Its Cash Wisely

We're Not Very Worried About SpectraCure's (STO:SPEC) Cash Burn Rate

Nov 09
We're Not Very Worried About SpectraCure's (STO:SPEC) Cash Burn Rate

Companies Like SpectraCure (STO:SPEC) Are In A Position To Invest In Growth

Jul 27
Companies Like SpectraCure (STO:SPEC) Are In A Position To Invest In Growth

Companies Like SpectraCure (STO:SPEC) Are In A Position To Invest In Growth

Mar 09
Companies Like SpectraCure (STO:SPEC) Are In A Position To Invest In Growth

SpectraCure (STO:SPEC) Is In A Good Position To Deliver On Growth Plans

Nov 08
SpectraCure (STO:SPEC) Is In A Good Position To Deliver On Growth Plans

SpectraCure (STO:SPEC) Is In A Good Position To Deliver On Growth Plans

Jul 26
SpectraCure (STO:SPEC) Is In A Good Position To Deliver On Growth Plans

We Think SpectraCure (STO:SPEC) Can Afford To Drive Business Growth

Mar 19
We Think SpectraCure (STO:SPEC) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About SpectraCure's (STO:SPEC) Cash Burn Situation

Nov 16
Here's Why We're Not Too Worried About SpectraCure's (STO:SPEC) Cash Burn Situation

We Think SpectraCure (STO:SPEC) Can Easily Afford To Drive Business Growth

Aug 03
We Think SpectraCure (STO:SPEC) Can Easily Afford To Drive Business Growth

We're Not Worried About SpectraCure's (STO:SPEC) Cash Burn

Apr 16
We're Not Worried About SpectraCure's (STO:SPEC) Cash Burn

Companies Like SpectraCure (STO:SPEC) Can Afford To Invest In Growth

Jan 01
Companies Like SpectraCure (STO:SPEC) Can Afford To Invest In Growth

Shareholder Returns

SPECSE Medical EquipmentSE Market
7D3.9%-4.0%-4.3%
1Y-56.5%-0.002%12.6%

Return vs Industry: SPEC underperformed the Swedish Medical Equipment industry which returned -0% over the past year.

Return vs Market: SPEC underperformed the Swedish Market which returned 12.6% over the past year.

Price Volatility

Is SPEC's price volatile compared to industry and market?
SPEC volatility
SPEC Average Weekly Movement6.4%
Medical Equipment Industry Average Movement7.1%
Market Average Movement5.8%
10% most volatile stocks in SE Market12.2%
10% least volatile stocks in SE Market3.4%

Stable Share Price: SPEC's share price has been volatile over the past 3 months.

Volatility Over Time: SPEC's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200313Masoud Khayyamiwww.spectracure.com

SpectraCure AB (publ) engages in the development of cancer treatment system. It develops Q-PRO, a laser device; and IDOSE software with interstitial photodynamic therapy system for the treatment of prostate cancer. The company was incorporated in 2003 and is based in Lund, Sweden.

SpectraCure AB (publ) Fundamentals Summary

How do SpectraCure's earnings and revenue compare to its market cap?
SPEC fundamental statistics
Market capSEK 232.63m
Earnings (TTM)-SEK 21.06m
Revenue (TTM)n/a

-122.5x

P/S Ratio

-11.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SPEC income statement (TTM)
Revenue-SEK 1.90m
Cost of Revenue-SEK 9.99m
Gross ProfitSEK 8.09m
Other ExpensesSEK 29.15m
Earnings-SEK 21.06m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.22
Gross Margin-425.86%
Net Profit Margin1,109.11%
Debt/Equity Ratio0%

How did SPEC perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.